Among these, Reparixin, a CXCR1/2 allosteric inhibitor, has demonstrated promising activity against breast cancer stem cells when used in combination with paclitaxel in a phase Ib clinical trial for human epidermal growth factor receptor 2 (HER-2) negative metastatic patients (NCT02370238)[106]. Here, ERBB2 is linked to breast cancer.